CSCO lung cancer guidelines update green leaf pharmaceutical Lipitor (R) is recommended as a first-line drug

On April 27, the Chinese society of Clinical Oncology (CSCO), the authoritative institution of oncology in China, issued the guideline for diagnosis and treatment of primary lung cancer of CSCO in 2019 in Nanjing Paclitaxel, an innovative preparation of LVYE pharmaceutical, has been recommended as a first-line drug by the latest CSCO guidelines CSCO guidelines, as the gold standard for Chinese clinicians to guide the clinical diagnosis and treatment of tumors, are the most academic guidelines in China The release of CSCO lung cancer diagnosis and treatment guidelines was co chaired by Professor Zhou caicun of Shanghai Lung hospital and Professor Cheng Ying of Jilin tumor hospital Professor Ren Shengxiang of Shanghai Lung hospital, Professor Wang Zhijie of Cancer Hospital of China Medical College and Professor Liu Jingjing of Jilin tumor hospital respectively pointed out the key points of updating the guidelines for advanced non-small cell lung cancer, early, local non-small cell lung cancer and small cell lung cancer South interpretation According to the guidelines, for the treatment of stage IV non-small cell lung cancer without driving gene, the first-line treatment recommendation of paclitaxel liposome combined with platinum is added, and the recommended level is level I; for the treatment of stage IV squamous cancer without driving gene, the first-line treatment recommendation of paclitaxel liposome combined with platinum is added, and the recommended level is level I; at the same time, the treatment plan of paclitaxel liposome combined with platinum is written "Common first-line chemotherapy for non-small cell lung cancer" In addition, it is noted in the guidelines that paclitaxel liposomes have better safety and tolerance, and the incidence of peripheral neuritis is reduced Paclitaxel liposome - Lipitor ® is an innovative preparation independently developed by green leaf pharmaceutical It uses liposome and targeted drug delivery technology to treat non-small cell lung cancer, breast cancer, ovarian cancer and other cancers LVYE pharmaceutical holds patent for the composition and formula of the drug Lipitor ® is the only paclitaxel liposome for injection in the world The drug encapsulates taxol which is difficult to dissolve in water in the bilayer of liposome, and no longer uses the mixture of polyoxyethylcastor oil and anhydrous ethanol, which is easy to cause serious allergic reaction On the premise of maintaining the specific efficacy of taxol, it improves the safety of clinical use of taxol and reduces adverse reactions In the past 15 years since its launch, the exact efficacy and better safety of Lipitor ® have been widely recognized by doctors and patients in long-term clinical practice According to iqvia data, Lipitor is the most commonly used anti-cancer drug in China in 2018 The management of LVYE Pharmaceutical Group said: "as a first-line drug writing guide, Lipitor ® will further improve the wider application of the product in relevant indications, provide an innovative and efficient treatment method for the vast number of lung cancer patients in China, improve the drug availability of patients, promote standardized treatment of patients, and ultimately improve the treatment results of patients." CSCO guidelines were written by the guidelines Working Committee of Chinese society of clinical oncology On the basis of evidence-based medicine and expert opinions, CSCO guidelines take into account the differences in diagnosis and treatment accessibility brought about by the imbalance of regional development CSCO guidelines are the gold standards for Chinese clinicians to guide clinical diagnosis and treatment of tumors, the most academic influential and the largest diagnosis and treatment guidelines in China, and more suitable for China's national conditions This guideline is of great significance to guide and promote the standardized diagnosis and treatment of tumors We believe that as a first-line drug, Lipitor ® will be written into CSCO lung cancer guidelines, which will provide further authoritative guidance for its wider and more standardized application in clinical treatment.